Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980235 | 0.88 | SIRT6 (0.51) | SIRT6MAPTALDH1A1LMNAPOLB | |
| SCHEMBL4827754 | 0.82 | MAPK14 (0.54) | SIRT6MAPTALDH1A1LMNAPOLB | |
| SCHEMBL7848917 | 0.81 | ALDH1A1 (0.49) | SIRT6MAPTALDH1A1LMNAPOLB | |
| SCHEMBL7614087 | 0.79 | KCNQ3 (0.54) | MAPTLMNANPC1RAB9AHTT | |
| SCHEMBL28676274 | 0.78 | SIRT6 (0.83) | SIRT6MAPTALDH1A1POLBNPC1 | |
| SCHEMBL2979467 | 0.77 | MAPT (0.50) | MAPTALDH1A1LMNAPOLBNPC1 | |
| SCHEMBL6883068 | 0.77 | SMN1; SMN2 (0.54) | MAPTALDH1A1LMNAPOLBNPC1 | |
| SCHEMBL2969766 | 0.77 | HDAC3 (0.51) | MAPTALDH1A1NPC1RAB9AHTT | |
| SCHEMBL2978967 | 0.76 | MAPT (0.58) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL4824273 | 0.76 | BRAF (0.65) | SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | SIRT6 336/4885MAPT 4431/4885ALDH1A1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.